A Bullseye for Children With Systemic Juvenile Idiopathic Arthritis
- PMID: 30802004
- PMCID: PMC6594873
- DOI: 10.1002/art.40867
A Bullseye for Children With Systemic Juvenile Idiopathic Arthritis
Comment on
-
Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.Arthritis Rheumatol. 2019 Jul;71(7):1163-1173. doi: 10.1002/art.40865. Epub 2019 May 25. Arthritis Rheumatol. 2019. PMID: 30848528 Free PMC article.
References
-
- Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis and rheumatism 2006. May;54(5):1595–601. - PubMed
-
- Janow G, Schanberg LE, Setoguchi S, Hasselblad V, Mellins ED, Schneider R, et al. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010–2013. The Journal of rheumatology 2016. September;43(9):1755–62. - PubMed
-
- Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology 2002. December;41(12):1428–35. - PubMed
-
- Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. The Journal of rheumatology 2000. February;27(2):491–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical